对c-Met和c-Srcc的宏环抑制剂TPX-0022的结构洞察力
Lingzhi Qu1, Hang Lin1, Shuyan Dai1
1Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Computational and structural biotechnology journal
|December 11, 2023
概括
一种针对c-Met,c-Src和CSF1R激酶的新型抑制剂TPX-0022对各种癌症突变表现出强大的活性. 结构分析揭示了它的结合机制,为克服先进的固体瘤中抗药性提供了洞察力.
科学领域:
- 在瘤学瘤学.
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- c-Met受体氨酸激酶是癌症治疗中的重要标,因为它在瘤生长和转移中的作用.
- TPX-0022是一种针对c-Met,c-Src和CSF1R的试验性宏环抑制剂,目前正在临床试验中,用于具有MET变化的高级固体瘤.
研究的目的:
- 通过共同晶体结构的确定,阐明TPX-0022与c-Met和c-Src的结合机制.
- 了解TPX-0022对各种c-Met抗性突变的活性.
主要方法:
- 确定了c-Met/TPX-0022和c-Src/TPX-0022复合物的共同晶体结构.
- 进行了生物化学测试,以评估TPX-0022对野生类型和c-Met的突变形式的活性.
主要成果:
- TPX-0022与c-Met和c-Src的ATP口袋结合,通过疏水和键相互作用稳定.
- TPX-0022对L1195F突变体表现出强烈的活性,对G1163R,F1200I和Y1230H突变体表现出适度的活性.
- 对c-Met D1228N和Y1230C突变物观察到较弱的活性,这表明对特定耐药性突变的差异性疗效.
结论:
- 该研究揭示了TPX-0022对c-Met和c-Src的强度和选择性的结构基础.
- TPX-0022证明了克服c-Met.中的获得性耐药性突变的潜力.
- 这些发现为开发下一代选择性c-Met宏循环抑制剂提供了宝贵的见解.
相关概念视频
Receptor Tyrosine Kinases
13.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.0K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


